2篇
您的检索式：作者名="Eric A Singer"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer显示文摘gonadal 睾丸激素合成的抑制首先代表标准为变形前列腺癌症的治疗的线治疗。在得阉割抵抗的前列腺癌症(CRPC ) 的病人的多数,然而,通过自己在肾上腺或在肿瘤以内生产的雄激素检测雄激素受体(AR ) 的坚持的激活是可能的。Abiraterone 醋酸盐作为 17 α 与活动作为双功能的细胞色素 P450 酶 CYP17 的一个不可逆的禁止者被开发; -hydroxylase 和 17,20-lyase。CYP17 为从胆固醇的 nongonadal 雄激素的生产是必要的。基于与 abiraterone 和泼尼松对泼尼松在全面幸存(OS ) 显示出重要改进的阶段 III 试用,在 2011 的 abiraterone 的规章的赞同代表了指向 AR 为与 CRPC 在人改进结果是必要的原则的证明。 17 α 的抑制;由 abiraterone 的 -hydroxylase 由于垂体的调停皮质醇的抑制的损失导致在上游的 mineralocorticoids 的累积促肾上腺皮质的荷尔蒙( ACTH ),为 17,20-lyase 为 CYP17 禁止者的开发向一个基本原理提供增加的特性( orteronel , galeterone 和 VT-464 )没有外长的 corticosteroids ,那能潜在地被管理。在这篇文章,我们考察 abiraterone 和另外的 CYP17 禁止者的发展;有 abiraterone 的最近的研究在 quality-of-life,反应的潜在的早预言者,并且关于另外的代理人的 abiraterone 的最佳的定序上通知我们的理解象药效果那样的临床的参数;并且提供卓见进抵抗机制给导致临床的试用,药联合设计了延长 abiraterone 利益或恢复 abiraterone 活动的 CYP17 禁止者的翻译研究结果。 | Mark N Stein | 2014 | Asian Journal of Andrology2014，16，3： | 3 |
| 2 | Combination drug regimens for metastatic clear cell renal cell carcinoma显示文摘Renal cell carcinomas(RCC)make up about 90%of kidney cancers,of which 80%are of the clear cell subtype.About 20%of patients are already metastatic at the time of diagnosis.Initial treatment is often cytoreductive nephrectomy,but systemic therapy is required for advanced RCC.Single agent targeted therapies are moderately toxic and only somewhat effective,leading to development of immunotherapies and combination therapies.This review identifies limitations of monotherapies for metastatic renal cell carcinoma,discusses recent advances in combination therapies,and highlights therapeutic options under development.The goal behind combining various modalities of systemic therapy is to potentiate a synergistic antitumor effect.However,combining targeted therapies may cause increased toxicity.The initial attempts to create therapeutic combinations based on inhibition of the vascular endothelial growth factor or mammalian target of rapamycin pathways were largely unsuccessful in achieving a profile of increased synergy without increased toxicity.To date,five combination therapies have been approved by the U.S.Food and Drug Administration,with the most recently approved therapies being a combination of checkpoint inhibition plus targeted therapy.Several other combination therapies are under development,including some in the phase 3 stage.The new wave of combination therapies for metastatic RCC has the potential to increase response rates and improve survival outcomes while maintaining tolerable side effect profiles. | Viraj V Khetani Daniella E Portal Mansi R Shah Tina Mayer Eric A Singer | 2020 | World Journal of Clinical Oncology2020，11，8： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员